马德里格尔制药

最新新闻

• 评级变动
  Wells Fargo Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $685
  \u5e02\u573a\u8d44\u8baf · 2026/7/27
• 评级变动
  Wolfe Research Upgrades Madrigal Pharmaceuticals(MDGL.US) to Buy Rating, Announces Target Price $605
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Citizens JMP Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $739
  \u5e02\u573a\u8d44\u8baf · 2026/7/17
• 评级变动
  Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL), Biogen (BIIB) and Cadrenal Therapeutics, Inc. (CVKD)
  TipRanks · 2026/7/14
• 评级变动
  Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Cuts Target Price to $962
  \u5e02\u573a\u8d44\u8baf · 2026/8/4
• 评级变动
  Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• 评级变动
  Truist Financial Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $709
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  TD Cowen Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $644
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  H.C. Wainwright Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $620
  \u5e02\u573a\u8d44\u8baf · 2026/7/31
• 评级变动
  BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Maintains Target Price $542
  \u5e02\u573a\u8d44\u8baf · 2026/7/14
• Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $962
  \u5e02\u573a\u8d44\u8baf · 2026/9/30
• 评级变动
  UBS Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $669
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  Barclays Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Maintains Target Price $964
  \u5e02\u573a\u8d44\u8baf · 2026/7/13
• Citi Initiates Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Announces Target Price $725
  \u5e02\u573a\u8d44\u8baf · 2026/9/23
• Goldman Sachs Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $704
  \u5e02\u573a\u8d44\u8baf · 2026/9/24
• 评级变动
  CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $612
  \u5e02\u573a\u8d44\u8baf · 2026/8/12
• Form 144 | Madrigal Pharmaceuticals(MDGL.US) Director Proposes to Sell 25.83 Million in Common Stocks
  \u5e02\u573a\u8d44\u8baf · 2026/9/29
• 评级变动
  BofA Securities Maintains Madrigal Pharmaceuticals(MDGL.US) With Hold Rating, Raises Target Price to $553
  \u5e02\u573a\u8d44\u8baf · 2026/7/22
• 评级变动
  CCORF Maintains Madrigal Pharmaceuticals(MDGL.US) With Buy Rating, Raises Target Price to $587
  \u5e02\u573a\u8d44\u8baf · 2026/7/29
• Earnings Flash (MDGL) Madrigal Pharmaceuticals, Inc. Reports Q2 Revenue $364.3M, Vs. FactSet Est of $352.1M
  MT Newswires · 2026/7/30

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。